Tae Won Kim

17.2k total citations · 3 hit papers
296 papers, 7.5k citations indexed

About

Tae Won Kim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Tae Won Kim has authored 296 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 226 papers in Oncology, 110 papers in Pulmonary and Respiratory Medicine and 66 papers in Pathology and Forensic Medicine. Recurrent topics in Tae Won Kim's work include Colorectal Cancer Treatments and Studies (170 papers), Gastric Cancer Management and Outcomes (66 papers) and Genetic factors in colorectal cancer (59 papers). Tae Won Kim is often cited by papers focused on Colorectal Cancer Treatments and Studies (170 papers), Gastric Cancer Management and Outcomes (66 papers) and Genetic factors in colorectal cancer (59 papers). Tae Won Kim collaborates with scholars based in South Korea, United States and Japan. Tae Won Kim's co-authors include Yong Sang Hong, Jae‐Lyun Lee, Yoon‐Koo Kang, Min‐Hee Ryu, Jin Cheon Kim, Chang Sik Yu, Heung Moon Chang, Jong Hoon Kim, Takayuki Yoshino and Se Jin Jang and has published in prestigious journals such as Journal of Biological Chemistry, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Tae Won Kim

287 papers receiving 7.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

2015 652 citations Takayuki Yoshino, Rocio García‐Carbonero et al. profile →
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

2014 339 citations Timothy Price, Marc Peeters et al. profile →
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial

2025 34 citations Takayuki Yoshino, Tae Won Kim et al. Nature Medicine profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Tae Won Kim	5.1k	2.5k	1.7k	1.5k	1.3k	296	7.5k
Maria Di Bartolomeo	4.7k 0.9×	2.4k 1.0×	1.4k 0.9×	982 0.7×	900 0.7×	248	6.5k
Joan Maurel	6.9k 1.4×	3.9k 1.6×	2.5k 1.5×	1.6k 1.1×	1.2k 1.0×	221	9.4k
Robert R. McWilliams	5.9k 1.2×	1.9k 0.8×	1.9k 1.1×	1.1k 0.8×	2.4k 1.8×	206	8.4k
Young Suk Park	4.0k 0.8×	2.3k 0.9×	1.9k 1.2×	738 0.5×	1.3k 1.0×	227	6.3k
Fausto Petrelli	5.9k 1.2×	3.2k 1.3×	2.3k 1.4×	1.2k 0.8×	1.3k 1.0×	280	9.1k
Bruno Landi	5.9k 1.2×	2.9k 1.1×	1.7k 1.0×	1.9k 1.3×	1.5k 1.2×	70	8.3k
Yuxian Bai	3.2k 0.6×	2.3k 0.9×	1.2k 0.7×	846 0.6×	1.5k 1.1×	187	6.0k
Vladimir Moiseyenko	5.6k 1.1×	4.1k 1.6×	1.8k 1.1×	701 0.5×	1.0k 0.8×	142	8.1k
Marinela Capanu	5.0k 1.0×	2.9k 1.1×	2.7k 1.6×	1.1k 0.8×	1.6k 1.2×	249	9.1k
Yoshito Komatsu	4.1k 0.8×	3.5k 1.4×	2.2k 1.3×	900 0.6×	984 0.8×	319	6.6k

Countries citing papers authored by Tae Won Kim

Since Specialization

Citations

This map shows the geographic impact of Tae Won Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tae Won Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tae Won Kim more than expected).

Fields of papers citing papers by Tae Won Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tae Won Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tae Won Kim. The network helps show where Tae Won Kim may publish in the future.

Co-authorship network of co-authors of Tae Won Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Tae Won Kim. A scholar is included among the top collaborators of Tae Won Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tae Won Kim. Tae Won Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pietrantonio, Filippo, Lisa Salvatore, Taito Esaki, et al.. (2025). Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer. Journal of Clinical Oncology. 43(19). 2147–2154. 7 indexed citations

Takashima, Atsuo, Pilar García‐Alfonso, Ali Ayberk Beşen, et al.. (2024). Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study. European Journal of Cancer. 205. 114036–114036. 7 indexed citations

Kim, Hyung‐Don, Ho Yeong Lim, Baek‐Yeol Ryoo, et al.. (2024). Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial. Nature Medicine. 30(3). 699–707. 29 indexed citations

Yang, Tsai‐Sheng, Hong‐Hwa Chen, Tae Won Kim, et al.. (2023). Prospective, open‐label, and observational study of cetuximab for metastatic colorectal carcinoma: The OPTIM1SE study. Asia-Pacific Journal of Clinical Oncology. 19(6). 672–680.

André, Thierry, Tae Won Kim, Benny Vittrup Jensen, et al.. (2023). LBA32 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study. Annals of Oncology. 34. S1271–S1272. 12 indexed citations

Hyung, Jaewon, Shinkyo Yoon, Changhoon Yoo, et al.. (2023). Safety and efficacy of trastuzumab biosimilar plus irinotecan or gemcitabine in patients with previously treated HER2 (ERBB2)-positive non-breast/non-gastric solid tumors: a phase II basket trial with circulating tumor DNA analysis. ESMO Open. 8(3). 101583–101583. 2 indexed citations

Kang, Sora, Sun Young Kim, Yong Sang Hong, et al.. (2023). CEA dynamics for predicting response after anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. Scientific Reports. 13(1). 6735–6735. 1 indexed citations

Garralda, Elena, Do Youn Oh, Antoîne Italiano, et al.. (2023). Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients with Mixed Solid Tumors (GO30103). The Journal of Clinical Pharmacology. 64(5). 544–554. 9 indexed citations

Oh, Ji‐Hye, Sungyang Jo, Kye Won Park, et al.. (2023). Whole-genome sequencing reveals an association between small genomic deletions and an increased risk of developing Parkinson’s disease. Experimental & Molecular Medicine. 55(3). 555–564. 6 indexed citations

10.

Cho, Eun Jeong, Minsuh Kim, Jihye Kim, et al.. (2021). Immuno-genomic classification of colorectal cancer organoids reveals cancer cells with intrinsic immunogenic properties associated with patient survival. Journal of Experimental & Clinical Cancer Research. 40(1). 230–230. 23 indexed citations

11.

Hong, Yong Sang, Ji Sung Lee, Keun‐Wook Lee, et al.. (2020). Effectiveness of Combining Bevacizumab With First-Line Chemotherapy Regimens for Metastatic Colorectal Cancer in Real-World Practice. Clinical Colorectal Cancer. 20(2). 101–112.e6. 6 indexed citations

12.

Park, Yu Rang, et al.. (2019). Expedited Safety Reporting to Sponsors Through the Implementation of an Alert System for Clinical Trial Management at an Academic Medical Center: Retrospective Design Study. JMIR Medical Informatics. 8(2). e14379–e14379. 1 indexed citations

13.

Kim, Tae Won, Marc Peeters, Anne Thomas, et al.. (2018). Impact of Emergent Circulating Tumor DNA RAS Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer. Clinical Cancer Research. 24(22). 5602–5609. 41 indexed citations

14.

Peeters, Marc, Timothy Price, Michael Boedigheimer, et al.. (2018). Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study. Clinical Cancer Research. 25(4). 1216–1225. 32 indexed citations

15.

Park, Yu Rang, et al.. (2018). Utilization of a Clinical Trial Management System for the Whole Clinical Trial Process as an Integrated Database: System Development. Journal of Medical Internet Research. 20(4). e103–e103. 21 indexed citations

16.

Lee, Sang Ju, Seung Jun Oh, Sun Young Chae, et al.. (2017). [18F]fluorothymidine PET Informs the Synergistic Efficacy of Capecitabine and Trifluridine/Tipiracil in Colon Cancer. Cancer Research. 77(24). 7120–7130. 6 indexed citations

17.

Choi, Yun Jung, Soyoung Yoo, Seong Yoon Kim, et al.. (2016). Knowledge and Perception about Clinical Research Shapes Behavior: Face to Face Survey in Korean General Public. Journal of Korean Medical Science. 31(5). 674–674. 16 indexed citations

18.

Jo, Jae‐Cheol, Ha‐Reum Lee, Dae‐Hee Lee, et al.. (2015). Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity. Molecular Cancer Therapeutics. 14(11). 2613–2622. 22 indexed citations

19.

Rho, Jin Kyung, Yun Jung Choi, Seon Ye Kim, et al.. (2013). MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation. Cancer Research. 74(1). 253–262. 120 indexed citations

20.

Hoff, Paulo M., Andreas Hochhaus, Bernhard C. Pestalozzi, et al.. (2012). Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II). Journal of Clinical Oncology. 30(29). 3596–3603. 112 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact